Navigation Links
Experimental Vaccine Seems to Cure Prostate Cancer in Mice
Date:6/20/2011

By Denise Mann
HealthDay Reporter

SUNDAY, June 19 (HealthDay News) -- Preliminary research shows that an experimental vaccine may cure prostate cancer in mice.

Unlike previous cancer vaccine attempts, the new prostate cancer vaccine appears to be smart enough to outfox prostate cancer tumors, but experts caution that the research is still in its infancy and has yet to be tested in humans.

The hunt for effective cancer treatment vaccines has been going on for decades with varying degrees of success early on, but the new prostate cancer vaccine takes a markedly different approach.

Instead of aiming at a few cancer-causing proteins or antigens on the tumor, the new vaccine casts a much a wider net. The goal of a cancer vaccine is to trick the body's immune system into recognizing the tumor as an invader and attacking it. This is typically done using a virus as a host.

The researchers developed a library of genetic material (DNA) from healthy human prostate tissue cells and then inserted them into a virus. The end product was intravenously injected into the mice, which recognized the antigens and launched a potent immune response, according to a report on the findings, published online June 19 in Nature Medicine.

The study reported no side effects, and none of the mice developed autoimmune diseases, which had been reported in previous cancer vaccine trials.

"Many cancer vaccines display one, two or few antigens and, although this is successful in alerting the immune system to the cancer, the tumor eventually outsmarts the vaccine and adapts," explained the study's lead author, Richard Vile, an immunologist and professor at the Mayo Clinic in Rochester, Minn.

Vile said he hopes that the new approach is smarter than the tumor. If the tumor adapts to the antigen, he explained, the vaccine launches a second wave of attacks.

The approach also makes the development easier, he said, as scientists don't have to identify specific antigens or targets. "We clone them all and let the immune system select which is most important," Vile said.

But, this may also prove to be a hurdle in getting U.S. Food and Drug Administration approval to study the vaccine in humans. "The FDA requires that the active proteins be well characterized, and we don't know which the active proteins are," Vile said.

Even so, he said, "we hope to try to put this vaccine into patients within the next three to five years."

Dr. J. Leonard Lichtenfeld, deputy chief medical officer for the American Cancer Society in Atlanta, said that news of the study "certainly holds out hope that this may represent a true advance."

He cautioned, though, that "we have been looking to vaccines for cancer for many decades and have not yet seen a vaccine or immune therapy make the leap from interesting concept to something effective in the clinic."

That said, the approach outlined in the new paper is "very different," Lichtenfeld said, adding that he remains cautiously optimistic about the vaccine.

"We have been excited in the past by some of these reports, and the success has not panned out," he said. "There is still a ways to go before we can get excited and say it will have benefit for patients with prostate cancer."

Willem W. Overwijk, a cancer vaccine researcher at the University of Texas MD Anderson Cancer Center in Houston, agreed. "We have to wait and see if it will work in people," he said. "They are inducing a broad immune response at many targets on the tumor, which makes it harder for the tumor to escape. [If it does], they make a new vaccine targeting the recurring tumor."

But the bottom line remains: "We have to see if this works the same way in people with prostate cancer," Overwijk said. "Stay tuned."

More information

The U.S. National Cancer Institute has more on prostate cancer.

SOURCES: Richard Vile, Ph.D., professor, immunology, Mayo Clinic, Rochester, Minn.; J. Leonard Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; Willem W. Overwijk, Ph.D., assistant professor, department of melanoma medical oncology research, division of cancer medicine, University of Texas MD Anderson Cancer Center, Houston; June 19, 2011, Nature Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Vaccine Seems to Cure Prostate Cancer in Mice
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: